Background While recent evidence has suggested that sarcopenia could predict
chemotoxicity, its association with chemotherapy‐triggered interstitial lung disease (ILD) …

Objectives It remains controversial whether sarcopenia has any significant impact on the
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) or …

Background Frailty, sarcopenia and malnutrition are powerful predictors of clinical outcomes
that are not routinely measured in patients with non-small cell lung cancer (NSCLC). The …

We intended to investigate whether muscle and adipose masses were associated with
prognosis among patients with stage III non-small-cell lung cancer (NSCLC) who were …

Objectives To assess the predictability value of Sarcopenia index ((SI, serum creatinine
value/cystatin C value× 100) in determining potential chemotherapy-induced undesirable …

Background Sarcopenia is prevalent and a known adverse prognostic effector in lung
cancer (LCA). However, the relationship between sarcopenia and histology remains …

Background Evidence regarding the association between sarcopenia (skeletal muscle
depletion) and outcomes in patients with lung cancer varies across studies. We aimed to …

Background Sarcopenia, characterised by an ongoing loss of skeletal muscle mass and
reduced strength and function, is frequently observed in patients with non-small cell lung …

Background In patients with cancer, sarcopenia is associated with treatment related
complications, treatment cessation, poor quality of life and reduced overall survival. Despite …

Background The association between sarcopenia and prognosis in patients with locally
advanced non-small cell lung cancer (NSCLC) undergoing trimodality therapy, consisting of …